DUBLIN--(BUSINESS WIRE)--The "Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment" report has been added to ResearchAndMarkets.com's offering.
The Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment market is expected to reach $34.1 billion by 2026 growing at a CAGR of 7.7% during the forecast period.
Increasing awareness regarding neuro-developmental disorders and easy availability of diagnostic guidelines over the internet is projected to boost the growth. However, underdiagnosis of ADHD due to the existence of comorbid conditions in children, lack of awareness and low availability of non-stimulant drugs to treat ADHD in various regions are likely to hamper the expansion of the global ADHD therapeutics market during the forecast period.
Based on the Age Group, the Adults segment is estimated to have a lucrative growth due to the high prevalence of the condition across the globe, increased awareness about mental health, and launch of effective drugs with minimum adverse effects.
The key vendors mentioned are Alcobra, Amarantus, Curemark, Eli Lilly and Company, Highland Therapeutics, Johnson & Johnson Services, LLC, Lupin, Mallinckrodt, Medice, NEOS Therapeutics Inc., Neurovance, Nextwave Pharmaceuticals, Novartis AG, Noven Pharmaceuticals, Pfizer, Prude Pharma L.P., Recordati, Rhodes Pharmaceuticals, Shionogi, and Shire.
Key Questions Answered in this Report
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
- Fastest growing markets analyzed during the forecast period
Key Topics Covered
1 Market Synopsis
2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources
3 Market Dynamics
3.1 Drivers
3.2 Restraints
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Drug
5.1 Introduction
5.2 Amphetamine
5.3 Atomoxetine
5.4 Bupropion
5.5 Clonidine
5.6 Dexmethylphenidate
5.7 Guanfacine
5.8 Lisdexamfetamine
5.9 Methylphenidate
5.10 Dextroamphetamine
6 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Type
6.1 Introduction
6.2 Non-Stimulants
6.3 Stimulants
7 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Age Group
7.1 Introduction
7.2 Adult (Aged 18 and above)
7.3 Children (2-17 years of age)
7.4 Pediatric and Adolescent
8 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Distribution Channel
8.1 Introduction
8.2 E-Commerce
8.3 Hospital Pharmacy
8.4 Retail Pharmacy
8.5 Specialty Clinics
9 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Geography
9.1 North America
9.2 Europe
9.3 Asia-Pacific
9.4 South America
9.5 Middle East & Africa
10 Strategic Benchmarking
11 Vendors Landscape
11.1 Alcobra
11.2 Amarantus
11.3 Curemark
11.4 Eli Lilly & Company
11.5 Highland Therapeutics
11.6 Johnson & Johnson Services, LLC
11.7 Lupin
11.8 Mallinckrodt
11.9 Medice
11.10 NEOS Therapeutics Inc.
11.11 Neurovance
11.12 Nextwave Pharmaceuticals
11.13 Novartis AG
11.14 Noven Pharmaceuticals
11.15 Pfizer
11.16 Prude Pharma L.P.
11.17 Recordati
11.18 Rhodes Pharmaceuticals
11.19 Shionogi
11.20 Shire
For more information about this report visit https://www.researchandmarkets.com/r/83gh97
